Israel’s TA-25 index advanced 1.5 percent, the most since Jan. 10, to 1,081.35, at the 4:30 p.m. close in Tel Aviv. Investors traded about 1.2 billion shekels ($318 million) of shares and convertible securities, according to bourse data.
The following stocks rose or fell today. Symbols are in parentheses.
BioLineRx Ltd. (BLRX) climbed 5 percent, the most since Feb. 20, to 1.216 shekels. The biopharmaceutical company received a U.S. patent application approval for its BL-1040 composition.
Cimatron Ltd. (CIMT) (CIMT IT) climbed 10 percent, the most since Aug. 4, to 13.90 shekels, giving the company a market value of 129 million shekels. The provider of software solutions for the tool-making and manufacturing industries said fourth-quarter profit increased.
Dexia Israel Bank Ltd. (DXIL) (DXIL IT) advanced 2.7 percent, the biggest gain since Dec. 21, to 441.60 shekels. The mortgage and lending bank said net income in the fourth quarter increased to 37.9 million shekels from 7.9 million shekels a year earlier.
Delek Drilling-LP (DEDRL) rose 2 percent, the most since Feb. 19, to 13.55 shekels. Avner Oil Exploration LLP (AVNRL) gained 2.4 percent, also the most since Feb. 19, to 2.48 shekels. Ratio Oil Exploration 1992 LP (RATIL) advanced 8.5 percent, the biggest gain since Nov. 13, to 0.344 shekel. The partners in the Leviathan gas field rose after Calcalist reported that a delegation from Russia’s Gazprom OAO discussed joint venture possibilities and investments in Leviathan with representatives of Houston-based Noble Energy Inc. and Delek Energy Systems Ltd.
Perrigo Co. (PRGO) , the largest U.S. maker of generic over-the-counter drugs, rose 2.8 percent to 379.30 shekels, the highest since Jan. 19. The U.S. Food & Drug Administration is considering rule changes that would allow more prescription drugs to be sold over-the-counter.
Teva Pharmaceutical Industries Ltd. (TEVA) advanced 1.6 percent, the biggest gain since Feb. 15, to 169.40 shekels. The Pharmachemie BV unit of the world’s largest generic drugmaker was approved by the U.S. Food & Drug Administration to sell preservative-free methotrexate, a treatment for cancer.
To contact the reporter on this story: Shoshanna Solomon in Tel Aviv at email@example.com
To contact the editor responsible for this story: Claudia Maedler at firstname.lastname@example.org